Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease - Scorecard - MDSpire

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • By

  • Qiumei Zhu

  • Shitao Feng

  • Zhende Yan

  • Zijian Wang

  • Xinran Huang

  • Changning Sun

  • Bingqiang Zhang

  • Xinrui Li

  • Yuchao Gu

  • July 2, 2026

  • 0 min

Share

Clinical Scorecard: Genetically Modified Escherichia coli Nissle 1917 Producing Anti-TNF-α Nanobody as a Novel Single-Strain Live Biotherapeutic for Treating Inflammatory Bowel Disease

At a Glance

CategoryDetail
ConditionInflammatory Bowel Disease (IBD)
Key MechanismsLocalized TNF-α neutralization via engineered probiotics
Target PopulationPatients with IBD, including Crohn’s disease and ulcerative colitis
Care SettingClinical settings for IBD treatment

Key Highlights

  • EcN-MT1 significantly reduced weight loss and improved disease activity index in murine colitis models.
  • Engineered EcN demonstrated high secretion levels of anti-TNF-α nanobody MT1.
  • Treatment restored gut microbial diversity and corrected dysbiosis.
  • EcN-MT1 showed potent suppression of pro-inflammatory cytokines in macrophages.
  • The study highlights the potential of live biotherapeutics for safer IBD therapies.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of IBD should consider clinical, endoscopic, and histological criteria.

Management

  • Consider engineered probiotics like EcN-MT1 for localized treatment of IBD.

Monitoring & Follow-up

  • Monitor disease activity index and mucosal healing in IBD patients.

Risks

  • Current treatments carry risks of systemic immunosuppression and opportunistic infections.

Patient & Prescribing Data

Patients with chronic inflammatory bowel disease.

EcN-MT1 offers a novel approach by delivering localized anti-inflammatory effects without systemic exposure.

Clinical Best Practices

  • Utilize engineered probiotics for targeted therapy in IBD.
  • Assess gut microbiota diversity as part of treatment evaluation.
  • Incorporate monitoring of pro-inflammatory cytokines in treatment plans.

Related Resources & Content

Original Source(s)

Related Content